SEARCH

SEARCH BY CITATION

References

  • 1
    Health Insurance Review and Assessment Service. Pharmacoeconomic Guidelines and Points to Prepare Submissions. Seoul, South Korea: Health Insurance Review And Assessment Service, 2006.
  • 2
    Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26:497511.
  • 3
    Bolin K, Mörk AC, Willers S, et al. Varenicline as compared to bupropion in smoking-cessation therapy—cost-utility results for Sweden 2003. Respir Med 2008;102:699710.
  • 4
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008;24:5161.
  • 5
    Lee HY, Yoon SJ, Ahn HS. Measuring the burden of major cancers due to smoking in Korea. Cancer Sci 2006;97:5304.
  • 6
    Korea Institute for Health and Social Affairs. The Third National Health and Nutrition Examination Survey. Seoul, South Korea: Korea Institute for Health and Social Affairs, 2005.
  • 7
    Jee SH, Jo IH, Yun JE, et al. Smoking and cause of death in Korea: 11 years follow-up prospective study. Korean J Epidemiol 2005;27:18290.
  • 8
    Korea National Statistical Office. National Statistical Office (2005) Annual report on the cause of death statistics. Available from: http://www.kosis.kr[Accessed September 1, 2007.
  • 9
    Health Insurance Review and Assessment Service. Construction of National Surveillance System for Cardiovascular and Cerebrovascular Disease. Seoul, South Korea: Health Insurance Review and Assessment Service, 2006.
  • 10
    Kojima S, Sakakibara H, Motani S, et al. Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population. J Epidemiol 2007;17:5460.
  • 11
    Ministry for Health, Welfare and Family Affairs. 1999–2001 Cancer Incidence in Korea (2005). Seoul, South Korea: Ministry for Health, Welfare and Family Affairs, 2005.
  • 12
    US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
  • 13
    Thun MJ. Smoking vs. other risk factors as the cause of smoking attributable deaths: confounding in the courtroom. JAMA 2000;284:70612.
  • 14
    Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:4755.
  • 15
    Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:5663.
  • 16
    Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:15618.
  • 17
    Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:15717.
  • 18
    Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:104056.